Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Eletriptan
Drug ID BADD_D00755
Description Eletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches.
Indications and Usage For the acute treatment of migraine with or without aura in adults.
Marketing Status approved; investigational
ATC Code N02CC06
DrugBank ID DB00216
KEGG ID D07887
MeSH ID C115647
PubChem ID 77993
TTD Drug ID D02DMQ
NDC Product Code Not Available
UNII 22QOO9B8KI
Synonyms eletriptan | (R)-3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole | UK 166,044 | UK-166044 | UK 166044 | UK-166,044 | Relpax | UK-116044-04 | UK-116,044-04 | eletriptan hydrobromide | (R)-3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole monohydrobromide | 3-(1-methyl-2-pyrrolidinylmethyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole hydrobromide
Chemical Information
Molecular Formula C22H26N2O2S
CAS Registry Number 143322-58-1
SMILES CN1CCCC1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urinary tract disorder20.08.01.001--Not Available
Urticaria23.04.02.001; 10.01.06.0010.003000%
Vaginal discharge21.08.02.002--
Vaginal infection21.14.02.002; 11.01.10.002--
Vascular purpura01.01.04.007; 24.07.06.011; 23.06.01.008--Not Available
Vasospasm24.04.02.002--Not Available
Ventricular arrhythmia02.03.04.006--
Ventricular fibrillation02.03.04.008--
Ventricular tachycardia02.03.04.010--
Vertigo17.02.12.002; 04.04.01.0030.000904%
Viral infection11.05.04.001--Not Available
Vision blurred17.17.01.010; 06.02.06.0070.001843%
Visual impairment06.02.10.0130.001590%Not Available
Vomiting07.01.07.0030.006289%
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Wheezing22.03.01.0090.000795%
Yawning22.12.03.037--Not Available
Coronary artery dissection12.02.01.035; 24.02.02.001; 02.02.01.0040.000723%Not Available
Hypoacusis04.02.01.0060.002024%
Deep vein thrombosis24.01.02.0030.000542%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Affect lability19.04.01.001--Not Available
Breast cancer female16.10.01.004; 21.05.01.0110.000542%Not Available
Major depression19.15.01.003--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Drug resistance08.06.01.0050.000361%Not Available
Urine output increased13.13.03.002--Not Available
Mental disorder19.07.01.0020.000795%Not Available
The 9th Page    First    Pre   9 10    Next   Last    Total 10 Pages